DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,412 filers reported holding DANAHER CORPORATION in Q3 2019. The put-call ratio across all filers is 0.78 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $604,981 | +65.7% | 2,751 | +148.1% | 0.01% | +350.0% |
| Q4 2021 | $365,000 | +22.9% | 1,109 | +13.6% | 0.00% | 0.0% |
| Q3 2021 | $297,000 | -67.3% | 976 | -71.2% | 0.00% | -60.0% |
| Q2 2021 | $909,000 | -25.4% | 3,387 | -37.4% | 0.01% | -44.4% |
| Q1 2021 | $1,218,000 | -9.6% | 5,412 | -10.8% | 0.01% | -10.0% |
| Q4 2020 | $1,347,000 | +326.3% | 6,065 | +313.1% | 0.01% | +150.0% |
| Q3 2020 | $316,000 | +16.2% | 1,468 | -4.7% | 0.00% | 0.0% |
| Q2 2020 | $272,000 | +15.7% | 1,540 | -9.3% | 0.00% | +33.3% |
| Q1 2020 | $235,000 | -61.0% | 1,697 | -56.8% | 0.00% | -50.0% |
| Q4 2019 | $603,000 | +128.4% | 3,929 | +114.7% | 0.01% | +100.0% |
| Q3 2019 | $264,000 | +5.6% | 1,830 | +4.6% | 0.00% | 0.0% |
| Q2 2019 | $250,000 | -19.9% | 1,750 | -25.9% | 0.00% | -25.0% |
| Q1 2019 | $312,000 | -50.6% | 2,362 | -63.1% | 0.00% | -42.9% |
| Q2 2018 | $632,000 | -41.5% | 6,404 | -42.0% | 0.01% | -46.2% |
| Q1 2018 | $1,080,000 | – | 11,034 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |